文献速递呼吸道感染呼吸危重症与机械通气

肺炎克雷伯菌肺炎噬菌体治疗进展

[Advances in phage therapy for pneumonia caused by Klebsiella pneumoniae].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2026-01-01

本综述系统梳理了噬菌体治疗肺炎克雷伯菌(KP)肺炎的临床前与临床证据,阐明噬菌体-宿主相互作用的分子机制,并评估了不断演进的治疗策略。碳青霉烯耐药KP肺炎病死率超过50%,噬菌体疗法作为替代或辅助策略,在动物模型和同情用药案例中显示出降低肺细菌负荷、减轻炎症损伤和改善生存的潜力。

要点

  • 碳青霉烯耐药KP肺炎病死率超过50%,噬菌体疗法是难治性感染的潜在替代或辅助策略。
  • 小鼠肺炎模型中,经鼻或雾化给予噬菌体可降低肺细菌负荷、减轻炎症损伤并改善生存。
  • KP通过受体修饰、核酸干扰和流产感染等机制抵抗噬菌体,需优化鸡尾酒和工程化噬菌体等策略。

核心结论

  • 噬菌体疗法是治疗难治性肺炎克雷伯菌感染的 promising 替代或辅助策略,临床前和初步临床证据支持其安全性和治疗潜力。

研究设计与样本

  • 本综述系统梳理了噬菌体治疗肺炎克雷伯菌肺炎的临床前与临床证据基础,并评估了分子机制和治疗策略。

主要发现

  • 碳青霉烯耐药KP所致肺炎病死率超过50%。
  • 小鼠肺炎模型中,经鼻或雾化给予噬菌体可显著降低肺细菌负荷、减轻炎症性肺损伤并改善生存,与常规抗生素联用常表现协同效应。
  • 临床病例报告和小规模同情用药系列为个性化噬菌体制剂治疗多重耐药KP肺炎危重患者提供了初步但有力的安全性和治疗前景证据。
  • 噬菌体通过识别细菌表面受体(主要为荚膜多糖,其次为脂多糖)介导裂解。
  • KP通过受体修饰、核酸干扰系统(如CRISPR-Cas和限制-修饰系统)及流产感染机制抵抗噬菌体。

关键数值与推荐

  • 优化策略包括合理设计噬菌体鸡尾酒、基因工程扩展宿主范围的噬菌体、人工智能辅助宿主范围预测及水凝胶封装等递送平台。
  • 正在推进的措施包括建立地理多样化的噬菌体库、实时监测噬菌体耐药性及开发噬菌体衍生酶产品。

临床怎么用

  • 对于常规治疗选择耗尽的危重多重耐药KP肺炎患者,个性化噬菌体制剂可作为同情用药考虑。
  • 噬菌体治疗需关注窄宿主范围和噬菌体耐药突变,可结合鸡尾酒、工程化噬菌体和耐药监测优化方案。

局限性

  • 机制复杂性、生产标准化和监管不确定性仍是噬菌体疗法面临的持续挑战。
  • 临床证据主要来自病例报告和小规模同情用药系列,尚缺乏大规模对照研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Klebsiella pneumoniae (KP) has emerged as a formidable nosocomial pathogen in the era of antimicrobial resistance, with mortality from pneumonia caused by carbapenem-resistant strains exceeding 50%. Phage therapy has re-emerged as a promising alternative or adjunctive strategy for managing refractory KP infections. This review consolidates the current preclinical and clinical evidence base, outlines the molecular mechanisms of phage-host interactions, and appraises evolving therapeutic approaches. Preclinical investigations in murine pneumonia models have consistently demonstrated that intranasal or nebulization phage administration markedly reduces pulmonary bacterial burden, attenuates inflammatory lung injury, and improves survival, often exhibiting synergistic effects when combined with conventional antibiotics. Clinical case reports and small compassionate-use series have further provided preliminary yet compelling evidence supporting the safety and therapeutic promise of personalized phage formulations in critically ill patients with multidrug-resistant KP pneumonia who have exhausted standard treatment options. Mechanistically, phage tropism is mediated through the specific recognition of bacterial surface receptors-principally capsular polysaccharide and, to a lesser extent, lipopolysaccharide-by phage-encoded receptor-binding proteins, culminating in bacterial lysis. In response, KP has evolved a multilayered defensive arsenal encompassing receptor modification to impede adsorption, nucleic acid interference systems (e.g., CRISPR-Cas and restriction-modification), and abortive infection mechanisms that curtail phage propagation at the population level. To surmount the inherent limitations of narrow host range and the inevitable emergence of phage-resistant mutants, a suite of optimization strategies is under active refinement, including rationally designed phage cocktails, genetically engineered phages with extended tropism, artificial intelligence-assisted host-range prediction, and innovative delivery platforms such as hydrogel encapsulation to enhance pulmonary bioavailability. Despite ongoing challenges in mechanistic complexity, manufacturing standardization, and regulatory uncertainty, current initiatives- such as the establishment of geographically diverse phage libraries, real-time surveillance of phage resistance, and the development of phage-derived enzyme products-hold promise for establishing precision phage therapy as a viable and sustainable component of the antimicrobial stewardship armamentarium. 在抗菌药物耐药时代,肺炎克雷伯菌(Klebsiella pneumoniae,KP)已成为一种棘手的院内病原体,碳青霉烯耐药菌株所致肺炎的病死率超过50%。噬菌体疗法已重新成为治疗难治性KP感染的替代或辅助策略。本综述系统梳理了当前临床前与临床证据基础,阐明了噬菌体-宿主相互作用的分子机制,并评估了不断演进的治疗策略。尽管在机制复杂性、生产标准化及监管不确定性方面仍面临持续挑战,但正在推进的各项举措——包括建立覆盖不同地域的噬菌体库、开展噬菌体耐药性的实时监测以及开发噬菌体衍生酶类产品——有望使精准噬菌体疗法成为抗菌药物管理体系中切实可行且可持续的组成部分。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Hu YW, Zhang Y, Ren Y, et al. [Advances in phage therapy for pneumonia caused by Klebsiella pneumoniae]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42557080. doi:10.3760/cma.j.cn112147-20251012-00632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。